Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CF101 Added to Methotrexate in Rheumatoid Arthritis
NCT00556894Phase 2Completed
- Sponsor
- Can-Fite BioPharma Ltd.
- Start
- Feb 2008
- Primary completion
- Mar 2009
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of piclidenoson in rheumatoid arthritis (RA) (3 arms), sponsored by Can-Fite BioPharma Ltd. Primary endpoint: American College of Rheumatology 20% Response at 12 weeks. Started Feb 2008; status: completed.
02
Drugs
piclidenoson
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00556894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00556894.